Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials-Reference-Cited by-同舟云学术

Efficacy and safety of PARP inhibitors in the treatment of advanced ovarian cancer: An updated systematic review and meta-analysis of randomized controlled trials

Published:2021-01 Issue: Volume:157 Page:103145
ISSN:1040-8428
Container-title:Critical Reviews in Oncology/Hematology
language:en
Short-container-title:Critical Reviews in Oncology/Hematology

Author:

Hao Jiatao,Liu Ying,Zhang Taohong,He Jinmei,Zhao Haoyi,An Ruifang,Xue Yan

Funder

the Department of Obstetrics and Gynecology

The First Affiliated Hospital of Xi'an Jiaotong University

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference50 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray;CA Cancer J. Clin.,2018

2. Epithelial ovarian cancer: evolution of management in the era of precision medicine;Lheureux;CA Cancer J. Clin.,2019

3. Frequency of symptoms of ovarian cancer in women presenting to primary care clinics;Goff;JAMA,2004

4. Ovarian cancer prevention and screening;Menon;Obstet. Gynecol.,2018

5. Epithelial ovarian cancer;Lheureux;Lancet,2019

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. The every woman study™ low- and middle-income countries edition protocol: A multi-country observational study to assess opportunities and challenges to improving survival and quality of life for women with ovarian cancer;PLOS ONE;2024-05-29

2. Comparison of Adverse Events Between PARP Inhibitors in Patients with Epithelial Ovarian Cancer: A Nationwide Propensity Score Matched Cohort Study;Targeted Oncology;2024-02-28

3. PARP inhibitor era in ovarian cancer treatment: a systematic review and meta-analysis of randomized controlled trials;Journal of Ovarian Research;2024-02-26

4. Comparison of survival outcomes between olaparib and niraparib maintenance therapy in BRCA-mutated, newly diagnosed advanced ovarian cancer;Gynecologic Oncology;2024-02

5. Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500);Journal of Medicinal Chemistry;2024-02-01